Bukwang Pharmaceutical Co., Ltd. logo

Bukwang Pharmaceutical Co., Ltd. (003000)

Market Closed
12 Jun, 06:30
KRX SM KRX SM
4,475. 00
+150
+3.4682%
416.86B Market Cap
- P/E Ratio
125% Div Yield
431,702 Volume
0 Eps
4,325
Previous Close
Add Transaction
Day Range
4,360 4,610
Year Range
3,200 9,890
Want to track 003000 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

003000 closed Friday higher at ₩4,475, an increase of 3.4682% from Thursday's close, completing a monthly decrease of -7.1577% or -₩345. Over the past 12 months, 003000 stock gained 18.2299%.
003000 pays dividends to its shareholders, with the most recent payment made on Nov 20, 2025. The next estimated payment will be in In 5 months on Nov 20, 2026 for a total of ₩50.
The last earnings report, released on Apr 20, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Bukwang Pharmaceutical Co., Ltd. has completed 13 stock splits, with the recent split occurring on Dec 29, 2020.
The company's stock is traded on one exchange.

003000 Chart

People also search for

Hyundai Motor Co.
647,000
+6.5898%
Hyundai Motor Co. Ltd.
244,500
+4.9356%
Hyundai Motor Co. Ltd. Preferred
256,500
+6.2112%
Hyundai Motor Co., Ltd. Preferred
257,000
+6.639%
Kia Corporation
167,500
+0.4197%

Bukwang Pharmaceutical Co., Ltd. (003000) FAQ

What is the stock price today?

The current price is ₩4,475.00.

On which exchange is it traded?

Bukwang Pharmaceutical Co., Ltd. is listed on KRX SM.

What is its stock symbol?

The ticker symbol is 003000.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 125%.

What is its market cap?

As of today, the market cap is 416.86B.

Has Bukwang Pharmaceutical Co., Ltd. ever had a stock split?

Bukwang Pharmaceutical Co., Ltd. had 13 splits and the recent split was on Dec 29, 2020.

Bukwang Pharmaceutical Co., Ltd. Profile

Specialty Retail Industry
Consumer Discretionary Sector
Sung-Gu Lee CEO
KRX SM Exchange
KR7003000007 ISIN
KR Country
615 Employees
- Last Dividend
29 Dec 2020 Last Split
- IPO Date

Overview

Bukwang Pharmaceutical Co., Ltd. stands as a prominent entity in the pharmaceutical sector, possessing a legacy since its inception in 1960. Headquartered in Seoul, South Korea, Bukwang has cemented its reputation domestically and internationally by developing, producing, and marketing a wide array of pharmaceutical products. The company's commitment to enhancing human health and well-being is reflected in its diverse product portfolio that spans across multiple therapeutic areas. With a strong focus on research and development, Bukwang continues to pioneer in unveiling innovative treatments, addressing unmet medical needs in fields such as endocrinology, gastroenterology, cardiology, oncology, and beyond. The dedication to quality and efficacy has propelled Bukwang into a leading position, offering an extensive range of pharmaceutical solutions from ethical drugs to over-the-counter medications and health supplements.

Products and Services

  • Ethical Drugs: Bukwang's ethical drugs cater to a variety of health conditions including diabetic peripheral neuropathy, hypothyroidism, toxic liver disease, chronic hepatitis, liver cirrhosis, and iron-deficiency anemia. These prescription medications are foundational to the company's portfolio, demonstrating a commitment to critical healthcare needs.
  • Over-the-Counter (OTC) Drugs: The company also provides an extensive range of OTC drugs, which include fever and pain relief medication, gastrointestinal medication, cold medication, and laxatives for constipation. This segment also comprises collagen supplements, multivitamin supplements, mouthwash, topical gels, oral health supplements, and omega-3 supplements, catering to everyday health and wellness.
  • Personal Products: Beyond pharmaceuticals, Bukwang extends its offerings to personal care with products like toothpaste, toothbrushes, and oral care products. These items underline the company's holistic approach to health, focusing on prevention and daily care.
  • Nutraceuticals and Health Functional Foods: Emphasizing the importance of nutrition in health, Bukwang offers nutraceuticals and health functional foods. These products are designed to supplement the diet and provide health benefits, supporting overall wellness and preventive healthcare.
  • Quasi Drugs: This category includes products that are not classified strictly as pharmaceuticals but offer therapeutic benefits. Bukwang's range in this area demonstrates its flexibility and adaptability in meeting diverse consumer health needs.
  • Development Pipeline: Bukwang is dedicated to innovation and the future of healthcare, with several promising projects in its development pipeline. This includes Lurasidone for schizophrenia and bipolar depression; JM-010 for treating dyskinesia in Parkinson's disease; SOL-804 for metastatic castration-resistant prostate cancer; AhR Inhibitor for solid tumors; PKR Inhibitor for neurodegenerative disorders; and a PD Program for Parkinson's disease. Each of these candidates highlights Bukwang's commitment to advancing treatment options and improving patient outcomes.

Contact Information

Address: 7, Sangdo-ro, Seoul, South Korea, 06955
Phone: 82 2 828 8114